Diagnostic Value of FibroTouch and Non-invasive Fibrosis Indexes in Hepatic Fibrosis with Different Aetiologies

Peng, Xu; Tian, Anmin; Li, Junfeng; Mao, Yongwu; Jiang, Ni; Li, Ting; Mao, Xiaorong

doi:10.1007/s10620-021-07049-4

Cited by 6 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sensitivity of CAP values in diagnosing hepatic steatosis at stages S1, S2 and S3 was 81.5%, 86.7% and 100.0%, respectively, and the specificity was 80.6%, 91.7% and 96.5%, respectively [ 31 ]. Additionally, LSM outperformed other noninvasive fibrosis indices, namely fibrosis 4 (FIB-4), aspartate aminotransferase-to-platelet ratio index (APRI) and γ-glutamyl transferase-to-platelet ratio index (GPRI), demonstrating significant superiority, albeit second to liver biopsy [ 32 ]. Therefore, we employed FibroTouch in place of liver puncture to measure the degree of steatosis and fibrosis.…”

Section: Discussionmentioning

confidence: 99%

Circulating Bone morphogenetic protein 9 (BMP9) as a new biomarker for noninvasive stratification of nonalcoholic fatty liver disease and metabolic syndrome

Yang,

Gu,

Wang

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is closely related to metabolic syndrome (MetS). Bone morphogenetic protein 9 (BMP9) is an essential factor in glucose, lipid and energy metabolism. This study aims to investigate whether BMP9 can serve as a serological marker for the severity of NAFLD or MetS. Blood samples, clinical data and FibroTouch test were collected from consecutively recruited 263 individuals in Shanghai East hospital. All the participants were divided into three groups: the healthy controls, nonalcoholic fatty liver (NAFL) group and nonalcoholic steatohepatitis (NASH) at-risk group according to the results of FibroTouch test and liver function. Serum BMP9 levels were measured by enzyme-linked immunosorbent assay. Serum BMP9 levels were positively correlated with transaminase, triglyceride, fasting plasma glucose, glycated hemoglobin (HbA1c) and uric acid while it showed a downward trend as the increasing number of MetS components. Furthermore, it differentiated NASH at-risk (58.13 ± 2.82 ng/L) from the other groups: healthy control (70.32 ± 3.70 ng/L) and NAFL (64.34 ± 4.76 ng/L) (p < 0.0001). Controlled attenuation parameter of liver fat and liver stiffness measurement were negatively correlated with BMP9 levels, while high-density lipoprotein levels were positively correlated. The risk of developing NAFLD increased along with elevated serum BMP9 and BMI, and a significantly higher risk was observed in men compared to women. BMP9 should be considered a protective factor for the onset and development of NAFLD, as well as a promising biomarker for the severity of the NAFLD and MetS.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating Bone morphogenetic protein 9 (BMP9) as a new biomarker for noninvasive stratification of nonalcoholic fatty liver disease and metabolic syndrome

Yang,

Gu,

Wang

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…Elastography test: The LSM of a candidate with PBC was measured by trained physicians using FibroTouch [ 15 – 20 ] and expressed in kilopascals (kPa). The median of 10 or more consecutive successfully tests was taken as the LSM value.…”

Section: Methodsmentioning

confidence: 99%

Prognostic significance of liver stiffness in patients with primary biliary cholangitis: validation of Baveno VII criteria

Ding,

Guo,

Cui

et al. 2023

Hepatol Int

View full text Add to dashboard Cite

Background The role of liver stiffness measurements (LSM) in patients with primary biliary cholangitis (PBC) remains to be further elucidated. Aims To clarify the prognostic role of LSM and to validate the “novel concepts” proposed by the Baveno VII Working Group. Methods An analysis of the prognostic significance of LSM was performed involving 672 patients. Results LSM and ΔLSM/ΔT were independent risk factors for liver decompensation, liver transplantation, or liver-related death (primary outcomes, p < 0.001, both). A rule of 5 kPa for LSM (10–15–20 kPa) could be used to denote progressively higher relative risks of primary outcomes. Patients with LSM < 10 kPa have a negligible 3-year risk of primary outcomes (< 1%). Cut-off values of 10 and 15 kPa can be used to classify PBC patients into low-, medium-, and high-risk groups. A clinically significant decrease in LSM, evaluated at 6, 12, or 24 months elastography tests, was associated with a substantially reduced risk of primary outcomes (p < 0.05, all), which can be defined as a decrease in LSM of > − 20% associated with LSM < 20 kPa or any decrease to LSM < 10 kPa. A clinically significant increase in LSM, evaluated at 6, 12, or 24 months elastography tests, was associated with a substantially raised risk of primary outcomes (p < 0.05, all), which can be defined as an increase in LSM of ≥ + 20% or any increase to LSM ≥ 15 kPa. Conclusions LSM can be used to monitor disease progression and predict long-term prognosis in patients with PBC.

show abstract

“…In the assessment of hepatic steatosis, scattering occurs when the incident ultrasonic wave encounters lipid droplets contained in hepatic cells. This results in increased ultrasonic attenuation, which correlates with the severity of fatty liver disease ( 17 , 18 ). According to the standards outlined in the Expert Consensus on Clinical Application of Transient Elastography (TE) and based on the liver fat attenuation results detected by FibroTouch, patients with MAFLD were diagnosed as having mild fatty liver (CAP 240–265 dB/m), moderate fatty liver (CAP 265–295 dB /m), or severe fatty liver (CAP > 295 dB/m) ( 19 ).…”

Section: Methodsmentioning

confidence: 99%

Effect of a High Protein, Low Glycemic Index Dietary Intervention on Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial

et al. 2022

View full text Add to dashboard Cite

Background:Metabolic dysfunction-associated fatty liver disease (MAFLD) affects people at an increasingly younger age. The primary treatment for patients with MAFLD is diet-induced weight loss; however, excessive dieting is poorly effective.ObjectivesThe aim of this trial was to evaluate whether a high protein and low glycemic index (HPLG) dietary intervention would result in improvement of controlled attenuation parameter (CAP) and related metabolic markers in MAFLD.MethodsA 12-week controlled, parallel-group, randomized intervention trial was performed. A number of 63 participants with MAFLD were enrolled and randomized between the HPLG dietary group and the balanced diet control group. Both diets had the same hypocaloric level and were prescribed ad libitum within food limit lists. The primary outcome was CAP. The main secondary outcomes were weight loss and improvement of metabolism-related indexes at week 12 after the program initiation.ResultsA total of 59 participants completed the intervention and were included in the final analysis. The mean age was 39.3 ± 8.9 years and 66.1% were men. In this trial, protein and carbohydrate intakes were significantly higher and lower, respectively, in the HPLG group compared to controls (p < 0.001). At week 12, CAP was significantly reduced in both groups (p < 0.001). However, a significantly greater reduction in liver fat was observed in the HPLG group compared to the control group (p = 0.011), with mean relative reductions of 30.90 dB/m (95% CI, 21.53 to 40.26, p < 0.001) and 15.43 dB/m (95% CI, 7.57 to 23.30, p < 0.001), respectively. From baseline to week 12, a significantly greater loss in bodyweight was recorded in participants in the HPLG group (6.52 kg; 95% CI, 5.50 to 7.54, p < 0.001) compared to control subjects (2.00 kg; 95% CI, 0.89 to 3.11, p = 0.001). Moreover, body fat percentage in the HPLG group was significantly reduced compared with the control group (p = 0.002). Within-group improvements in visceral fat, blood pressure, cardiovascular risk factors, and blood glucose-related indicators were detected in patients with MAFLD assigned to the HPLG diet (p < 0.05), but not in those prescribed the control diet (p > 0.05).ConclusionUnder our experimental conditions, and compared to the traditional balanced diet, an HPLG diet led to a significant CAP remission, bodyweight or fat reduction, and improvement of metabolic markers in patients with MAFLD.Clinical Trial RegistrationClinicalTrials.gov, identifier: NCT03972631.

show abstract

Diagnostic Value of FibroTouch and Non-invasive Fibrosis Indexes in Hepatic Fibrosis with Different Aetiologies

Cited by 6 publications

References 35 publications

Circulating Bone morphogenetic protein 9 (BMP9) as a new biomarker for noninvasive stratification of nonalcoholic fatty liver disease and metabolic syndrome

Circulating Bone morphogenetic protein 9 (BMP9) as a new biomarker for noninvasive stratification of nonalcoholic fatty liver disease and metabolic syndrome

Prognostic significance of liver stiffness in patients with primary biliary cholangitis: validation of Baveno VII criteria

Effect of a High Protein, Low Glycemic Index Dietary Intervention on Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial

Contact Info

Product

Resources

About